Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is intended for the treatment of adult patients with FRα-positive, platinum-resistant high grade serous epithelial ovarian, Fallopian tube, or primary peritoneal cancer
Primary results from the DESTINY-Breast12 study
Findings from the TOPGEAR study
Findings from the AMBASSADOR study
Evidence for efficacy is based on the results from the MARIPOSA-2 study
Findings from the PSMAfore study
Findings from a randomised phase II study
Evidence for efficacy is based on the results from the KEYNOTE-483 study
Evidence for efficacy is based on the results from the AEGEAN study
Findings from the TROPHY-U-01 Cohort 2 study
Fundings from the LMS04 study
Evidence for efficacy is based on the results from the PERSEUS study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
